Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.

The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr Nephrol (2011) 2.13

Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol (2015) 1.75

Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2011) 1.67

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol (2010) 1.51

Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol (2013) 1.46

Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Pediatr Nephrol (2016) 1.40

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int (2013) 1.33

New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol (2011) 1.19

Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol (2009) 0.96

Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl (2011) (2012) 0.95

Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol (2015) 0.93

Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol (2015) 0.85

The problem of transition from pediatric to adult healthcare in patients with steroid-sensitive nephrotic syndrome (SSNS): a survey of the experts. Clin Exp Nephrol (2014) 0.81

Recurrent focal segmental glomerulosclerosis: a discrete clinical entity. Int J Nephrol (2012) 0.79

Rituximab for troublesome cases of childhood nephrotic syndrome. World J Clin Pediatr (2014) 0.78

Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol (2010) 0.78

Long-term Outcomes of Childhood Onset Nephrotic Syndrome. Front Pediatr (2016) 0.77

Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and Susceptibility of Minimal Change Nephrotic Syndrome: A Meta-Analysis. Int J Nephrol (2011) 0.77

Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience. Turk Pediatri Ars (2015) 0.75

The need for a children's oncology group-oriented approach to advance the care of children with Idiopathic nephrotic syndrome. Clin J Am Soc Nephrol (2009) 0.75

Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients. Sci Rep (2017) 0.75

American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis. Clin J Am Soc Nephrol (2014) 0.75

Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient. CEN Case Rep (2013) 0.75

Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep (2016) 0.75

A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood. BMC Res Notes (2015) 0.75

Study on Steroid Induced Ocular Findings in Children with Nephrotic Syndrome. J Clin Diagn Res (2017) 0.75

Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. CEN Case Rep (2013) 0.75

Pediatrics: how 'minimal' are the adult consequences of childhood MCNS? Nat Rev Nephrol (2010) 0.75

Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open (2017) 0.75

Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome. Kidney Res Clin Pract (2017) 0.75

REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. BMJ Open (2017) 0.75

Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02

Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser (1995) 57.68

A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis (2004) 6.66

Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med (2004) 3.87

Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics (1987) 3.43

Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. Am J Hum Genet (1999) 2.44

Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol (1997) 1.92

[CBO guideline 'Osteoporosis' (second revision]. Ned Tijdschr Geneeskd (2002) 1.81

NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest (2002) 1.81

Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol (2000) 1.67

Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). Kidney Int (2004) 1.64

Long-term outcome for children with minimal-change nephrotic syndrome. Lancet (1985) 1.52

The etiology of steroid cataract. J Ocul Pharmacol Ther (2007) 1.47

Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome. Hum Mutat (2001) 1.38

NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int (2004) 1.35

A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol (2001) 1.30

Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis (2003) 1.28

Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr (2005) 1.25

Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Nephrol Dial Transplant (2008) 1.22

Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics (2007) 1.17

Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy. Ophthalmologica (2006) 1.06

Nephrotic syndrome: from toddlers to twenties. Lancet (1989) 1.03

Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2003) 1.02

Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant (2005) 0.97

Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol (2003) 0.97

Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. Invest Ophthalmol Vis Sci (2007) 0.96

Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis (2007) 0.95

Ocular complications of paediatric patients with nephrotic syndrome. Clin Experiment Ophthalmol (2001) 0.93

Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med (2004) 0.92

Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int (2005) 0.92

Genetics of focal segmental glomerulosclerosis. Pediatr Nephrol (2007) 0.89

Potassium channel and NKCC cotransporter involvement in ocular refractive control mechanisms. PLoS One (2008) 0.88

Gonadal function in males treated with cyclophosphamide for nephrotic syndrome. Fertil Steril (1979) 0.87

Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. Exp Eye Res (1985) 0.87

Effects of dexamethasone on human lens epithelial cells in culture. Mol Vis (2008) 0.86

Pituitary-gonadal function in women following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol (1990) 0.84

Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol (2003) 0.84

Evaluation of reproductive functions in male adolescents following renal transplantation. Pediatr Transplant (2008) 0.82

Genetic polymorphism of NPHS1 modifies the clinical manifestations of Ig A nephropathy. Lab Invest (2003) 0.81

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82

Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20

Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80

Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology (2012) 3.52

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24

Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85

Gitelman syndrome. Orphanet J Rare Dis (2008) 2.81

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32

Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30

The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25

Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23

The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13

Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol (2009) 2.12

Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J Pathol (2013) 2.12

Reasons for dropout in an in vitro fertilization/intracytoplasmic sperm injection program. Fertil Steril (2004) 2.05

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04

Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02

Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00

Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol (2013) 1.94

Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol (2013) 1.90

A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87

PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86

Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol (2009) 1.85

Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 1.80

Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80

Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood (2011) 1.79

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol (2006) 1.78

18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 1.75

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant (2002) 1.74

Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71

Homozygous mutation in SPATA16 is associated with male infertility in human globozoospermia. Am J Hum Genet (2007) 1.71

18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69

Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem (2010) 1.68

Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66

Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2012) 1.64

Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61

99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61

Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57

Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet (2010) 1.57

Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis (2005) 1.56

Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56

Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int (2012) 1.55

Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55

PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55

F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54

Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int (2010) 1.52

Urinary protein excretion pattern and renal expression of megalin and cubilin in nephropathic cystinosis. Am J Kidney Dis (2008) 1.50

Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med (2008) 1.50

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer (2007) 1.50

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging (2010) 1.48

Validation of the kidney failure risk equation in European CKD patients. Nephrol Dial Transplant (2013) 1.48

A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47

Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med (2010) 1.46

A generalized concept of power helped to choose optimal endpoints in clinical trials. J Clin Epidemiol (2006) 1.45

Bone SPECT reduces the number of unnecessary mandibular resections in patients with squamous cell carcinoma. Oral Oncol (2005) 1.44

Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant (2005) 1.42

99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med (2002) 1.41

Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial. Catheter Cardiovasc Interv (2014) 1.40

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol (2012) 1.40

Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract (2003) 1.39

Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer (2006) 1.38

Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med (2006) 1.37

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35

Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2003) 1.34

Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med (2006) 1.34

The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol (2009) 1.33

Using online health communities to deliver patient-centered care to people with chronic conditions. J Med Internet Res (2013) 1.32

Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med (2006) 1.32

Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril (2006) 1.31

Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med (2007) 1.31

Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2011) 1.30

Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med (2010) 1.30

MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol (2008) 1.30

Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging (2003) 1.30

Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol (2011) 1.30

Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transplant (2012) 1.29

The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer (2005) 1.29

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29

Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrol Dial Transplant (2010) 1.28

A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun (2007) 1.27

18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med (2010) 1.27

Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med (2009) 1.26

Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging (2010) 1.26

2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol (2005) 1.26

Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation (2004) 1.26

The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol (2010) 1.25

Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int (2012) 1.24

Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24

Cystinosis: practical tools for diagnosis and treatment. Pediatr Nephrol (2010) 1.24

A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging (2006) 1.24